丁苯酞联合阿司匹林与氯吡格雷治疗进展性缺血性脑卒中的效果分析

Effect of Butylphthalein Combined with Aspirin and Clopidogrel in the Treatment of Progressive Ischemic Stroke

目的:分析丁苯酞联合阿司匹林与氯吡格雷治疗进展性缺血性脑卒中的效果。方法:选取2022年7月—2023年12月梅州市平远县人民医院收治的进展性缺血性脑卒中患者91例为研究对象,采用随机数字表法分为丁苯酞组(n=51)与常规治疗组(n=40)。常规治疗组给予阿司匹林联合氯吡格雷治疗,丁苯酞组在常规治疗组基础上给予丁苯酞治疗。比较两组临床疗效、凝血功能[纤维蛋白原(FIB)、D-二聚体(D-D)、血浆凝血酶时间(TT)及活化部分凝血活酶时间(APTT)]、出血性转化发生率及不良反应发生率。结果:丁苯酞组总有效率高于常规治疗组(P=0.024);治疗后,两组FIB、D-D水平下降,TT、APTT延长,丁苯酞组优于常规治疗组(P<0.05);丁苯酞组出血转化总发生率低于常规治疗组(P=0.044);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:丁苯酞联合阿司匹林与氯吡格雷治疗进展性缺血性脑卒中的效果确切,有利于改善患者凝血功能,降低出血性转化风险,且未增加不良反应发生率。

Objective:To analyze the effect of butylphthalein combined with aspirin and clopidogrel in the treatment of progressive ischemic stroke.Methods:Ninety-one patients with progressive ischemic stroke admitted to Meizhou Pingyuan County People's Hospital from July 2022 to December 2023 were selected as the study objects,and were divided into butophthalein group(n=51)and conventional treatment group(n=40)by random number table method.The treatment group was treated with aspirin combined with clopidogrel,and the butylphthalein group was treated with butylphthalein based on the treatment group.The clinical efficacy,coagulation function[fibrinogen(FIB),D-dimer(D-D),plasma thrombin time(TT)and activated partial thromboplastin time(APTT)],incidence of hemorrhagic conversion and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of butylphthalein group was higher than that of treatment group(P=0.024);after treatment,FIB and D-D levels decreased,TT and APTT prolonged,butylphthalein group was better than treatment group(P<0.05);the total incidence of hemorrhage conversion in butylphthalein group was lower than that in treatment group(P=0.044);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Butylphthalein combined with aspirin and clopidogrel has a definite effect in the treatment of progressive ischemic stroke,which is conducive to improving the coagulation function of patients,reducing the risk of hemorrhagic transformation,and does not increase the incidence of adverse reactions.